Celebrex is not an antidepressant. It is a nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA to treat pain and inflammation from conditions like osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. However, the question isn’t as far-fetched as it might sound. Researchers have been studying whether Celebrex’s anti-inflammatory properties could help with depression when added to standard antidepressant treatment, and some early results have been intriguing.
What Celebrex Actually Does
Celebrex (celecoxib) belongs to a specific class of NSAIDs called COX-2 inhibitors. It works by blocking an enzyme called cyclooxygenase-2, which plays a central role in producing inflammation throughout the body. The FDA has approved it for six uses: osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (in children 2 and older), ankylosing spondylitis, acute pain in adults, and painful menstrual cramps. None of these are psychiatric conditions, and Celebrex has no FDA approval for treating depression or any mood disorder.
Why Researchers Tested It for Depression
The connection between inflammation and depression has become one of the more active areas in psychiatric research. A significant subset of people with depression show elevated markers of inflammation in their blood, and scientists have been trying to understand whether reducing that inflammation could ease depressive symptoms.
The COX-2 enzyme that Celebrex targets is found in key brain regions involved in mood regulation, including the hippocampus and the prefrontal cortex. When this enzyme is overactive, it can promote a chain of harmful effects: it increases the release of glutamate (a brain chemical that, in excess, damages neurons), triggers immune cells in the brain to become overactive, and interferes with the brain’s ability to form healthy neural connections. In animal studies, celecoxib has been shown to calm this overactive immune response in the brain while boosting levels of serotonin and norepinephrine in the prefrontal cortex. Those are the same two chemical messengers that most conventional antidepressants target.
This biological overlap is what led researchers to wonder whether adding Celebrex to an antidepressant might produce better results than an antidepressant alone.
What the Clinical Evidence Shows
A meta-analysis pooling data from four studies with 150 patients found that people who took celecoxib alongside a standard antidepressant improved significantly more than those who took a placebo alongside the same antidepressant. The difference on a standard depression rating scale was about 3.3 points, which is considered clinically meaningful. More striking were the remission and response rates: patients in the celecoxib group were roughly six to seven times more likely to respond to treatment or achieve full remission compared to the placebo group.
Those numbers sound impressive, but context matters. The studies were small, and all four tested celecoxib as an add-on to existing antidepressant therapy, not as a standalone treatment. Celebrex was never pitted against a placebo on its own to see if it could treat depression by itself.
The results also haven’t been consistent across all mood disorders. A large, well-designed trial published in The Lancet Psychiatry tested celecoxib for bipolar depression and found no benefit. Over 12 weeks, depression scores dropped in all groups, but patients taking celecoxib fared no better than those on placebo. This suggests that whatever anti-inflammatory benefit celecoxib may offer, it doesn’t apply uniformly to every type of depression.
Who Might Be Studied Next
Researchers are now trying to identify which specific patients might benefit. One ongoing clinical trial is enrolling people with major depression who also have measurable signs of inflammation in their blood, specifically elevated C-reactive protein levels above 1 mg/L, along with symptoms like fatigue and low energy. The trial uses 400 mg of celecoxib daily for 12 weeks. The idea is that targeting inflammation may only help when inflammation is actually part of the problem, rather than treating all depression as if it has the same underlying cause.
No major psychiatric organization currently includes celecoxib in its standard treatment guidelines for depression. Experts in the field have noted that because no anti-inflammatory treatment is FDA-approved for depression, off-label use should generally be limited to patients who haven’t responded to conventional options.
Risks Worth Knowing About
Even if celecoxib eventually proves useful for certain depression subtypes, it carries real risks that distinguish it from typical psychiatric medications. The FDA’s label includes two boxed warnings, the most serious safety alerts the agency issues.
The first involves cardiovascular risk. Celebrex may increase the chance of heart attack and stroke, and this risk grows with longer use. People with existing heart disease or risk factors face the greatest danger, and the drug is completely off-limits for pain management around coronary artery bypass surgery.
The second warning covers gastrointestinal harm. Celebrex can cause stomach bleeding, ulcers, and intestinal perforation, sometimes without any warning symptoms beforehand. Older adults and people with a history of stomach ulcers are especially vulnerable. These risks are why celecoxib isn’t something to experiment with casually, even if the early depression research looks promising. The potential for serious physical side effects sets it apart from most medications prescribed for mood disorders.